Journal Watch · Journal of Immunology · 2026

Deficiency of microRNA-10a in CD4+ T cells protects against intestinal infection through mitochondrial oxidation-IL-22 pathway.

Together, these findings identify miR-10a as a T cell-intrinsic regulator of mitochondrial oxidative metabolism that constrains IL-22 production in the intestine.

Yang W, Yu T, Yao S, Cong YJournal of Immunology3 min readPharma relevance 30/100

DOI: 10.1093/jimmun/vkag089PMID: 42044496Study type: preclinical (animal / model) study

TL;DR

Together, these findings identify miR-10a as a T cell-intrinsic regulator of mitochondrial oxidative metabolism that constrains IL-22 production in the intestine.

Key findings

  • Pharmacologic inhibition of mitochondrial complex III with antimycin A suppressed the enhanced IL-22 production in miR-10a-deficient T cells.
  • We further identified Uqcrq, a subunit of mitochondrial complex III, as a direct target of miR-10a, and loss of Uqcrq suppressed IL-22 production in CD4+ T cells.
  • Together, these findings identify miR-10a as a T cell-intrinsic regulator of mitochondrial oxidative metabolism that constrains IL-22 production in the intestine.

What they did

MiR-10a deficiency led to increased IL-22 production in CD4+ T cells both in vitro and in vivo, under steady and inflammatory conditions. CD4+ T cell-specific miR-10a knockout mice were resistant to Citrobacter rodentium infection, and the protection was abolished when blocking the IL-22 pathway in mice. Mechanistically, miR-10a-deficient CD4+ T cells exhibited increased mitochondrial oxidative metabolism and membrane potential.

Full abstract (original)

Background: Interleukin 22 (IL-22) produced by CD4+ T cells plays an important role in regulating intestinal immune responses during inflammation and infection, but the mechanisms controlling IL-22 expression in T cells remain incompletely understood. MicroRNA-10a (miR-10a) is known to regulate CD4+ T-cell function, but its role in IL-22 production has not been defined. Here, using mouse CD4+ T cell-specific miR-10a knockout models, we examined how miR-10a regulates IL-22 expression and the underlying metabolic mechanisms.

What they did: MiR-10a deficiency led to increased IL-22 production in CD4+ T cells both in vitro and in vivo, under steady and inflammatory conditions. CD4+ T cell-specific miR-10a knockout mice were resistant to Citrobacter rodentium infection, and the protection was abolished when blocking the IL-22 pathway in mice. Mechanistically, miR-10a-deficient CD4+ T cells exhibited increased mitochondrial oxidative metabolism and membrane potential.

Results & conclusions: Pharmacologic inhibition of mitochondrial complex III with antimycin A suppressed the enhanced IL-22 production in miR-10a-deficient T cells. We further identified Uqcrq, a subunit of mitochondrial complex III, as a direct target of miR-10a, and loss of Uqcrq suppressed IL-22 production in CD4+ T cells. Together, these findings identify miR-10a as a T cell-intrinsic regulator of mitochondrial oxidative metabolism that constrains IL-22 production in the intestine.

Abstract © the authors / Journal of Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/jimmun/vkag089 · PubMed 42044496.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Journal of Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Immunology study find?

Together, these findings identify miR-10a as a T cell-intrinsic regulator of mitochondrial oxidative metabolism that constrains IL-22 production in the intestine.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Immunology in 2026. MiR-10a deficiency led to increased IL-22 production in CD4+ T cells both in vitro and in vivo, under steady and inflammatory conditions.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/jimmun/vkag089. PubMed ID: 42044496. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yang W, Yu T, Yao S, Cong Y. Deficiency of microRNA-10a in CD4+ T cells protects against intestinal infection through mitochondrial oxidation-IL-22 pathway.. Journal of Immunology (2026). DOI: 10.1093/jimmun/vkag089.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/deficiency-of-microrna-10a-in-cd4-t-cells-protects-against-intestinal-in-kag089/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides